In this issue:
1- vs. 2-step GDM screening
Semaglutide in overweight/obese adults with type 2 diabetes
Trends in diabetes incidence
Anti-IL-21 + liraglutide for preserving β-cell function in recent-onset type 1 diabetes
Glucose-lowering therapies and COVID-19 mortality risk in type 2 diabetes
Predictors of hospital discharge and mortality in diabetics with COVID-19
Early-phase in-hospital glycaemic fluctuation and mortality in COVID-19
Imeglimin in type 2 diabetes
Adjunctive hepatoselective glucokinase activator (TTP3969) in type 1 diabetes
Coformulated pramlintide/insulin analogue in type 1 diabetes
Please login below to download this issue (PDF)